Advances in the management of hepatitis B
- PMID: 40461178
- DOI: 10.1136/bmj-2024-079579
Advances in the management of hepatitis B
Abstract
Hepatitis B virus infection remains a pervasive global health challenge, affecting an estimated 254 million people worldwide. This review summarizes the current landscape of hepatitis B, including its epidemiology and the clinical spectrum of acute and chronic infection. It discusses the interplay between host and virus that underlies the progression from acute hepatitis to chronic liver disease, cirrhosis, and hepatocellular carcinoma. The review further examines current screening practices, diagnostic methods, and staging tools, as well as providing an in-depth evaluation of antiviral treatment strategies guided by randomized clinical trials and international consensus. Particular emphasis is placed on emerging therapeutic approaches. Drawing on high quality evidence from large scale epidemiological studies, rigorous clinical trials, and evolving global guidelines, this review not only encapsulates the state of the art in the management of hepatitis B but also highlights critical gaps and future directions. This synthesis is intended to inform clinicians and researchers alike, offering insights that may enhance patient care and guide future research toward the ultimate goal of elimination of hepatitis B.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests within the past 36 months: research grant support from Abbvie, Janssen, Boehringer, BMS, and GSK to RC’s institution; RC has served on scientific advisory boards for GSK and Precision Biosciences.
Similar articles
-
Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):499-512. doi: 10.1586/egh.09.50. Expert Rev Gastroenterol Hepatol. 2009. PMID: 19817672 Review.
-
Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.Expert Rev Gastroenterol Hepatol. 2017 Dec;11(12):1095-1104. doi: 10.1080/17474124.2017.1361822. Epub 2017 Aug 7. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28752768 Review.
-
NIH consensus development statement on management of hepatitis B.NIH Consens State Sci Statements. 2008 Oct 22-24;25(2):1-29. NIH Consens State Sci Statements. 2008. PMID: 18949020
-
Australian consensus recommendations for the management of hepatitis B.Med J Aust. 2022 May 16;216(9):478-486. doi: 10.5694/mja2.51430. Epub 2022 Mar 6. Med J Aust. 2022. PMID: 35249220
-
Hepatitis B virus infection in children and adolescents.Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. doi: 10.1016/S2468-1253(19)30042-1. Epub 2019 Apr 11. Lancet Gastroenterol Hepatol. 2019. PMID: 30982722 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical